Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tanhuo Bolus
- Development stage
- Unknown
- Lead developer
- Shanghai Kaibao Pharmaceutical
- Administration
- Oral
01
Overview
Tanhuo Bolus is a Traditional Chinese Medicine (TCM) formulation developed by Shanghai Kaibao Pharmaceutical for the treatment of acute ischemic stroke, specifically targeting the phlegm-heat syndrome. In TCM theory, phlegm-heat is a common pathological pattern in the acute phase of stroke, and Tanhuo Bolus is designed to clear heat and resolve phlegm to improve neurological outcomes. The drug is currently being evaluated in a Phase II randomized, double-blind, placebo-controlled multicenter clinical trial in China to assess its efficacy and safety in adult patients diagnosed with the phlegm-heat pattern of acute ischemic stroke.
- Brand names
- Tanhuo Bolus
- Other names
- Tanhuo Wan痰火丸
02
Targets
DNA
Beyond the preview
Go deeper on Tanhuo Bolus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tanhuo Bolus.